Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

(2018) Gianni Bisogno et al.   LANCET ONCOLOGY

Is there a role for salvage re-irradiation in pediatric patients with locoregional recurrent rhabdomyosarcoma? Clinical outcomes from a multi-institutional cohort

(2018) Daniel V. Wakefield et al.   RADIOTHERAPY AND ONCOLOGY

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

(2018) Douglas S. Hawkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-dose Cyclophosphamide

(2018) Dana L. Casey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy

(2017) Ralph P. Ermoian et al.   PEDIATRIC BLOOD & CANCER

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group

(2015) Suzanne L. Wolden et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

(2014) David A. Rodeberg et al.   INTERNATIONAL JOURNAL OF CANCER

Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma

(2014) Matthew M. Ladra et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study

(2012) Kavita V. Dharmarajan et al.   PEDIATRIC BLOOD & CANCER

Effect of Radiotherapy Techniques (IMRT vs. 3D-CRT) on Outcome in Patients With Intermediate-Risk Rhabdomyosarcoma Enrolled in COG D9803—A Report From the Children’s Oncology Group

(2011) Chi Lin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803—A Report From the Children's Oncology Group

(2010) A. Yuriko Minn et al.   JOURNAL OF CLINICAL ONCOLOGY

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY